Probing the serum albumin binding site of fenamates and photochemical protein labeling with a fluorescent dye

Binding studies of potential amyloid-β inhibiting chalcone derivative with bovine serum albumin

Chalcones (α-phenyl-β-benzoylethylene) and their natural-source derivatives have been investigated for their remarkable biological activities, like neuroprotective, anti-inflammatory, and anti-tumor properties. A triazole chalcone ligand (E)-3-(4-(dimethylamino)phenyl)-1-(4-((1-(2-(4-((E)-3-(4(dimethylamino)phenyl)acryloyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)prop-2-en-1-one (L1) was synthesized by Cu(I)- catalysed click reaction. The mechanistic properties of L1 for therapy were evaluated by analyzing the binding interactions between L1 and bovine serum albumin (BSA) through photophysical and computational studies. The structural elucidation of ligand L1 was carried out by NMR and mass spectrometry. The Aβ inhibitory activity of L1 was studied by thioflavin T assay and transmission electron microscopy. The biomolecular interaction of L1 with bovine serum albumin was examined through multi-spectroscopic techniques in combination with in silico studies. UV-Visible absorption, fluorescence spectroscopy, circular dichroism, Förster resonance energy transfer, and three-dimensional fluorescence studies confirmed the formation of a BSA-L1 complex. The potential binding sites, mechanism of interactions, and variations in the environment of tyrosine and tryptophan amino acid residues of BSA were assessed at different temperatures. The binding constant for the Static quenching mechanism of intrinsic fluorescence of BSA was of the order of 105 M-1. The esterase enzyme activity assay in the presence of L1 revealed an increase in the protein enzyme activity. Molecular docking studies suggested L1 was predominantly bound to BSA by hydrogen bonds and Van der Waals forces.

Improved Analytical Performance of an Amphiphilic Probe upon Protein Encapsulation: Spectroscopic Investigation along with Computational Rationalization

An easily synthesizable pyrene-based amphiphilic probe (Pybpa) has been developed, which exhibited no responses with metal ions in the pure aqueous medium despite possessing a metal ion-chelating bispicolyl unit. We believe that spontaneous aggregation of Pybpa in aqueous medium makes the ion binding unit not accessible to the metal ions. However, the sensitivity and selectivity of Pybpa toward Zn²⁺ ions drastically improve in the presence of serum albumin protein, HSA. The differences in the microenvironment inside the protein cavity, in terms of local polarity, and conformational rigidity might be attributing factors for that. The mechanistic investigations also suggest that there might be the involvement of polar amino acid residues that take part in coordination with Zn²⁺ ions. Pybpa shows no detectable spectroscopic changes with Zn²⁺ ions in aqueous medium in the absence of HSA. However, it can effectively recognize Zn²⁺ ions in the protein-bound form. Moreover, the photophysical behavior of Pybpa and its zinc complex have been investigated with DFT and docking studies. Noteworthy, such an unusual sensing aspect of Zn²⁺ exclusively in the protein-bound state and particularly in aqueous medium is truly rare and innovative.

Using Human Serum Albumin Binding Affinities as a Proactive Strategy to Affect the Pharmacodynamics and Pharmacokinetics of Preclinical Drug Candidates

We report on a new preclinical drug optimization strategy that measures drug candidates' binding affinity with human serum albumin (HSA) as an assessment of increasing or decreasing serum T1/2. Three common scaffolds were used as drug prototypes. Common polar and nonpolar substituents attached to the scaffolds have been identified as opportunities for increasing or decreasing the HSA binding affinity. This approach of adjusting HSA binding could be proactively established for preclinical drug candidates by appending functionality to sites on the drug scaffold not involved in biological target interactions. This strategy complements other medicinal chemistry efforts to identify longer or shorter human dosing regimens.